Staidson Beijing Biopharma (300204) - Total Liabilities
Based on the latest financial reports, Staidson Beijing Biopharma (300204) has total liabilities worth CN¥486.07 Million CNY (≈ $71.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Staidson Beijing Biopharma - Total Liabilities Trend (2007–2025)
This chart illustrates how Staidson Beijing Biopharma's total liabilities have evolved over time, based on quarterly financial data. See 300204 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Staidson Beijing Biopharma Competitors by Total Liabilities
The table below lists competitors of Staidson Beijing Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elevra Lithium Limited
AU:ELV
|
Australia | AU$205.99 Million |
|
Vir Biotechnology Inc
NASDAQ:VIR
|
USA | $212.82 Million |
|
Karooooo Ltd
NASDAQ:KARO
|
USA | $2.49 Billion |
|
Innovative Industrial Properties Inc
NYSE:IIPR
|
USA | $474.57 Million |
|
Exail Technologies S.A.
PA:EXA
|
France | €700.40 Million |
|
Redfin Corp
NASDAQ:RDFN
|
USA | $1.23 Billion |
|
Keystone Microtech Corp
TWO:6683
|
Taiwan | NT$653.58 Million |
|
UroGen Pharma Ltd
NASDAQ:URGN
|
USA | $377.94 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Staidson Beijing Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Staidson Beijing Biopharma (300204) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Staidson Beijing Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Staidson Beijing Biopharma (2007–2025)
The table below shows the annual total liabilities of Staidson Beijing Biopharma from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥459.48 Million ≈ $67.24 Million |
+97.33% |
| 2024-12-31 | CN¥232.85 Million ≈ $34.07 Million |
-25.26% |
| 2023-12-31 | CN¥311.55 Million ≈ $45.59 Million |
-1.24% |
| 2022-12-31 | CN¥315.45 Million ≈ $46.16 Million |
+14.19% |
| 2021-12-31 | CN¥276.25 Million ≈ $40.42 Million |
+2.81% |
| 2020-12-31 | CN¥268.70 Million ≈ $39.32 Million |
+18.27% |
| 2019-12-31 | CN¥227.18 Million ≈ $33.24 Million |
-27.72% |
| 2018-12-31 | CN¥314.30 Million ≈ $45.99 Million |
-25.01% |
| 2017-12-31 | CN¥419.14 Million ≈ $61.33 Million |
-3.05% |
| 2016-12-31 | CN¥432.32 Million ≈ $63.26 Million |
+11.69% |
| 2015-12-31 | CN¥387.06 Million ≈ $56.64 Million |
+30.09% |
| 2014-12-31 | CN¥297.54 Million ≈ $43.54 Million |
+16.47% |
| 2013-12-31 | CN¥255.47 Million ≈ $37.38 Million |
+32.96% |
| 2012-12-31 | CN¥192.15 Million ≈ $28.12 Million |
+306.05% |
| 2011-12-31 | CN¥47.32 Million ≈ $6.92 Million |
-52.03% |
| 2010-12-31 | CN¥98.66 Million ≈ $14.44 Million |
+239.79% |
| 2009-12-31 | CN¥29.03 Million ≈ $4.25 Million |
-0.73% |
| 2008-12-31 | CN¥29.25 Million ≈ $4.28 Million |
-39.50% |
| 2007-12-31 | CN¥48.35 Million ≈ $7.07 Million |
-- |
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mou… Read more